MedTrace Logo

Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

NCT01228019 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1166

Last updated 2015-04-21

Study results available
· View outcomes & findings →

Summary

This survey is being conducted to assess the safety and efficacy of niacin (+) laropiprant (TREDAPTIVE) in usual practice in Korea according to the new product re-examination regulations of the Korean Food and Drug Administration.

Conditions

Interventions

DRUG

Niacin (+) laropiprant

Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-05-31
Completion
2013-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228019 on ClinicalTrials.gov